Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
1.020
+0.010 (0.99%)
Nov 20, 2024, 4:00 PM EST - Market closed
Adial Pharmaceuticals Employees
As of December 31, 2023, Adial Pharmaceuticals had 7 total employees, including 4 full-time and 3 part-time employees. The number of employees decreased by 13 or -65.00% compared to the previous year.
Employees
7
Change (1Y)
-13
Growth (1Y)
-65.00%
Revenue / Employee
n/a
Profits / Employee
-$1,863,856
Market Cap
6.53M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Syra Health | 162 |
Zhongchao | 142 |
Aptose Biosciences | 36 |
Healthcare Triangle | 31 |
Addex Therapeutics | 23 |
ABVC BioPharma | 19 |
NLS Pharmaceutics AG | 7 |
CNS Pharmaceuticals | 5 |
ADIL News
- 15 days ago - Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer - GlobeNewsWire
- 2 months ago - Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - GlobeNewsWire
- 2 months ago - Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewsWire
- 3 months ago - Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 3 months ago - Adial Pharmaceuticals Announces Last Patient Dosed in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - GlobeNewsWire
- 4 months ago - Adial Pharmaceuticals Files New Patent Application to Protect Core Assets and Extend IP Exclusivity on Core Technology to 2044 - GlobeNewsWire
- 4 months ago - Adial Pharmaceuticals Advances to Second Cohort in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder - GlobeNewsWire
- 5 months ago - Adial Pharmaceuticals Announces Publication in Leading Peer-Reviewed Journal Supporting the Potential Efficacy of AD04 as a Precision Medicine for the Treatment of Alcohol Use Disorder - GlobeNewsWire